TechJournal South
Header

Archive for March, 2010

Slate Capital buys Coastal Business Machines

Wednesday, March 31st, 2010

slate capital loglBALTIMORE, MD – Baltimore-based private equit group Slate Capital Group, has acquired Coastal Business Machines in an asset buy.

Financial details of the transaction were not disclosed.

The Randallstown, MD-based company is the world’s largest reconditioning and repair center for uninterruptible power supplies.

CBM says it is the only company in the United States to be factory trained by APC for component level repair, and the company is also North America’s largest after-warranty battery replacement and repair center

KEYW nears $10M in mixed securities financing

Wednesday, March 31st, 2010

HANOVER, MD – KEYW Holding Corp. has raised $8 million of a targted $10 million mixed securities offering, according to a regulatory filing. The company sells a variety of IT solutions.

Founded in 2008, KEYW has acquired eight companies, including:

Insight Information Technology, The Analysis Group, Systems Engineering and Technical Assistance Unit, Government Contracting Assets of Leading Edge Design and Systems Inc., Embedded Systems Design Inc., Globecomm Systems (NASDAQ: GCOM), Integrated Computer Concepts, and S&H Enterprises.

KEYW’s business includes capabilities include: hardware and software development, systems engineering and integration, test and evaluation, field support, computer and network operations, information security and specialized training, collaboration and workflow, service-oriented architectures and complex event processing and data acquisitions, embedded systems and network protocols.

www.keywcorp.com

One Size Does Not Fit All: The Basics of Startup Company Capitalization

Wednesday, March 31st, 2010

By Glen Caplan, Hutchison Law Group

RESEARCH TRIANGLE, NC – When it comes to startups, one type of equity does not fit all. Below, I’ve outlined several common equities that startup companies issue based on an individual’s role within the company.

Founders

Often referred to as “Founders’ Stock”, founders typically purchase shares of the company’s Common Stock at the time of inception via a combination of cash (to help capitalize the company and to cover startup costs such as legal, accounting, and other initial operating expenses) and by contributing intellectual property to the company (such as the business plan, software code, trade secrets and other inventions relating to the business).

What makes Founders’ Stock unique, is that although the founder owns the shares, can vote the shares and can receive all economic benefit from the shares, the shares are typically subject to reverse vesting – meaning the company has a contractual right to repurchase all or a portion of the shares in the event the founder ceases to provide service to the company.

The schedule by which the company’s right to repurchase the shares lapses will vary from company to company, however, a typical vesting schedule is 25% of the shares are released from the company’s right of repurchase after one year, and the remaining shares are released in equal installments over the course of the next 36 months.

This repurchase right serves several important functions:

• It is a good mechanism to deal with the free rider problem that can arise when you have multiple founders. A founder who leaves the company after just a few months probably should not have the same equity interest as a founder who continues to provide service to the company for many years – you will often hear investors refer to the working founder’s equity as “sweat equity”.
• It gives a team some period of time to attempt to work together and determine who the core team will be, without irrevocably giving away a significant equity stake in the company if a co-founder is not going to work out in the long-term.

• It protects the company’s investors who will invest in the company’s management team just as much as its technology by locking in key members of management and aligning financial incentives with those of the investors.

Employees

Employees typically receive stock options as their ownership stake. A stock option is the contractual right to purchase a certain number of shares (almost always Common Stock) at a predetermined price (referred to as the exercise or strike price) at some point in the future (generally, within 10 years of the date of grant).

Options are almost always subject to vesting – though, unlike with Founders’ Stock, the optionee cannot exercise the option until it has vested – and can be, but are not always, subject to acceleration. The vesting schedule described above is also typical for an option.

Investors

Investors will fund the operation of the company by investing cash to purchase their equity interests. More often than not, they will purchase Preferred Stock, which is a class of stock that is granted certain rights, preferences and privileges that are superior to those of the Common Stock. You may have heard how investors can impose onerous terms on entrepreneurs or even assume control of the company post-investment. The special rights granted to the Preferred Stock is how this is accomplished.

Conclusion

The information above is only a general overview of this topic. For a more in-depth look, read the full article.  Also, as no two situations are ever the same, make sure you consult your attorney before implementing a formal capitalization plan for your company.

About the author:

Glen Caplan

Glen’s practice consists of counseling emerging growth technology and life science companies across a broad spectrum of sectors, including networking, software systems and applications, consumer electronics, video games, retail, biotechnology, pharmaceuticals and medical devices.

 

Hutchison Law Group, founded in 1996, represents many of the premier technology and life science companies in the Southeast. The firm provides venture capital financing advice, merger and acquisition counsel, licensing assistance, securities law advice and intellectual property protection, employment law advice and counseling, and other business legal services to a wide variety of businesses at all stages of development.

Intrinergy lands strategic investment from Riverstone

Wednesday, March 31st, 2010

RICHMOND, VA – Intrinergy, a company that specializes in biomass sourcing, processing and delivery and energy production, has received a strategic investement in an undisclosed amount from Riverstone Holdings.

Intrinergy operates in the Southeast and Midwest United States and in Europe.

Intrinergy CEO John Kepler said, “Demand for biomass from utilities and consumers committed to clean energy and carbon reduction will soon outstrip biomass resources available in Europe. This, along with rising demand for biomass in North America, creates significant opportunities for Intrinergy, a company with operations in both continents.”

Riverstone’s investment will enable Intrinergy to acquire and develop low-cost wood pellet operations and other fiber processing assets, principally in the Southeastern United States and other selected regions. This will position the company to extend its ability to offer sustainable, carbon-neutral biomass to many of the world’s largest utilities that seek to reduce their carbon footprint.

Pentaho nails $7M fourth round for open source business intel

Tuesday, March 30th, 2010

pentaho_logoORLANDO -Pentaho Corp., which sells open-source business intelligence software, has raised a $7 million fourth round financing, according to a regulatory filing.

The company previously raised $25 million in venture capital from investors who include Menlo Park, Calif.-based Benchmark Capital, UK-based Index Ventures and Baltimore-based New Enterprise Associates. It closed its $12 million C round in 2008.

Founded in 2004, Pentaho’s customer list includes Cox Communications, Delta Dental, Lifetime Networks, Monsanto Corporation, Savvion, Sun Microsystems, Terra Industries, U.S. Naval Air Command, and Wachovia.

The company disclosed the funding in a filing with the U.S. Securities and Exchange Commission.

Pentaho sells a BI Suite Enterprise Edition that provides comprehensive reporting, OLAP analysis, dashboards, data integration, data mining and a BI platform. The company says it is the world’s most widely deployed open source BI suite.

Peantho was one of TechJournal South’s Tech 50 companies in 2008.

www.pentaho.com

Damballa closes C round with GRA Venture Fund investment

Tuesday, March 30th, 2010

ATLANTA – Damballa, which says it is the only network security company that enables organizations to take back command-and-control from botnets and other remote-control criminal threats, has finalized its Series C financing with an investment from Atlanta’s GRA Venture Fund. The firm did not disclose the amount of the funding, but according to a filing with the U.S. Securities and Exchange Commission, it was targeted at $9 million.

Damballa’s new round of investment was led by Palomar Ventures. Current investors InterWest Partners, Noro-Mosely Ventures and Sigma Partners all participated in this round.

According to a filing with the SEC, the round was targeted at $9 million and the company closed on $8.2 million of it in October (see TechJournal South’s report (Damballa locks up about $8.2M of $9M round for botnet security tech).

Damballa’s approach to network security finds previously unidentified threats then closes the hidden two-way communications channels that cybercriminals use to manipulate compromised corporate systems.

The Atlanta-based company points out that these attacks are silent, stealthy and the weapon of choice for online attacks, fraud and abuse.

The GRA Venture Fund LLC is a private investment fund created to help finance promising companies that have emerged from the Georgia Research Alliance VentureLab commercialization program. Since 2002, GRA’s VentureLab has evaluated the commercial potential of more than 500 inventions or discoveries at Georgia’s research universities.

www.damballa.com

NeurOP inks deal with Bristo-Myers Squibb worth up to $74M

Tuesday, March 30th, 2010

ATLANTA – NeurOP Corp. has inked a collaboration deal with Bristol-Myers Squibb (NYSE:BMY) focused on developing new treatments for people with major depression who fail to get relief from current treatments.

The deal includes a $1.5 million upfront payment and funds a two-year research collaboration. It also includes the potential for NeurOP to nab up to $75 million in potential milestone payments for for the successful development of a compound in major depression and royalties on worldwide sales of commercialized compounds.

It is developing a compound class comprised of NR2B subunit-specific N-methyl-D-aspartate (NMDA) receptor antagonists.

We think NeurOP has a shot a making considerable chunks of cash. A large number of people who suffer from depression find only temporary or insufficient relief from current medications. The famous writer David Foster Wallace recently hanged himself when he could not find a suitable anti-depressant medicine and he is only one of many people who suffer from what Winston Churchill called “The Black Dog.”

The company also has technology aimed at pain relief, another sure-fire money-maker if it works better than products already available.

“NeurOp’s collaboration with Bristol-Myers Squibb will explore new treatment options for the millions of patients suffering from major depression who are unable to get relief from available treatments,” added Vincent La Terza, head of corporate development, NeurOp.

NeurOp has offices and laboratory facilities in EmTech Bio, a life sciences incubator located on the campus of Emory University in Atlanta, Georgia.

The company has raised $2.2MM to date through grants and convertible debt instruments with angel investors led by The Blue Grass Angels.

In 2000, the NeurOp founders initiated a collaboration with Dr. Dennis Liotta, a professor in the Emory Department of Chemistry to translate these promising concepts into medicines.

Dr. Liotta is a renowned medicinal chemist and has helped discover and develop several pharmaceuticals currently in use or undergoing clinical evaluation. About 75 percednt of all HIV patients worldwide are treated with antiviral compounds discovered or developed in Dr. Liotta’s lab.

TechJournal South attending CEO Council New Talent Exchange Wednesday

Tuesday, March 30th, 2010

ATLANTA – TechJournal South will be attending the New Talent Exchange sponsored by the MIT Enterprise Forum and Atlanta CEO Council  tomorrow (Wednesday, March 31) at Gordon Biersch Buckhead from 5 to 7 p.m. in Atlanta.

The New Talent Exchange is designed to help those new to the working world get a foothold in the Atlanta technology community by bringing them together with professionals from the technology, business and law communities.

Color-coded nametags will assist with networking pairings for a portion of the evening.

“This is the fourth New Talent Exchange we have presented, “said Virginia Martin, director of the MIT Enterprise Forum. “It’s a popular event for us and the perfect avenue for young professionals and their more seasoned counterparts to exchange ideas and business cards in an atmosphere that encourages success.”

TechJournal South/TechView Atlanta Editor Allan Maurer will attend the event.

For more information or to buy tickets to the event see: www.mitforumatlanta.org

Emory, Zirus Inc. developing new type of anti-viral drugs

Tuesday, March 30th, 2010

A macrophage capturing a virus coated in antibodies

A macrophage capturing a virus coated in antibodies.

ATLANTA – The Emory Institute of Drug Discovery and Zirus Inc., a biotechnology company based in Buford, Georgia, have entered into a collaboration and research agreement to develop novel compounds to treat infectious disease. In the lab, the underlying Zirus technology has already stopped viruses that cause flu, AIDS,herpes, measles, Ebola, and dengue fever, among others, from replicating.

Zirus uses a proprietary method for identifying genes and gene products in host cells that, when blocked, can prevent viruses from multiplying. Over the past several years, either alone or in collaboration with partners, including the Centers for Disease Control and Prevention (CDC), Zirus has identified, licensed and filed patents on more than 1000 targets.

Zirus has also identified a number of drugs already approved for indications other than infectious disease that appear to block Zirus targets. These drugs have the potential to reach the market quickly to address significant unmet medical needs for infectious diseases.

William O’Brien, M.D., CMO of Zirus stated, “Over the years viruses have shown that they can outsmart vaccines and anti-viral drugs such as protease inhibitors by mutating and developing resistance.

“As a result, there is no effective vaccine for HIV, each year we need a new vaccine for the seasonal flu, the effectiveness of vaccines for variations of swine flu and avian flu remain questionable, and the cocktail of drugs taken by AIDS patients is constantly changing.

“Each of these viruses, however, share a common element; they must invade our cells (human host cells) and hijack our genetic machinery in order to reproduce (Video of how flu viruses replicate) The Zirus technology allows us to identify which genes and pathways are employed by the viruses inside our cells, and by blocking them we can stop the virus from replicating.

David Perryman, CEO of Zirus, added, “The collaboration with Emory is designed as a true partnership between Zirus and a world class group of chemists with a track record of designing successful drugs.”

The Emory team is being led by Dennis Liotta, the Samuel Candler Dobbs Professor of Chemistry and head of the Emory Institute of Drug Discovery.

Liotta said, “While I have successfully worked for many years developing anti-viral drugs, the Zirus approach to blocking host cell genes and gene products represents a new paradigm in dealing with infectious disease that may address some of the shortcomings of conventional programs. Infectious disease needs a multi-prong attack, and the Zirus host targets appear to represent the ‘third leg of the stool’ along with vaccines and traditional anti-virals that attack the virus.

The Emory Institute for Drug Discovery was established in August 2009, with the dual mission of carrying out early-stage discovery and preclinical drug research aimed at developing small-molecule therapeutics and training new generations of researchers in a multidisciplinary drug discovery environment.

Chrysalis Ventures names executive-in-residence

Tuesday, March 30th, 2010

janesse-thaw-bruce

Janese Thaw Bruce

LOUISVILLE, KY – Chrysalis Ventures has named Janesse (Jan) Thaw Bruce as its new Executive-in-Residence.

As Executive-in-Residence, Thaw Bruce is responsible for evaluating new business opportunities and assisting current portfolio companies in both the technology and healthcare sectors. In her role, Ms. Jarchow will support Chrysalis’ business development efforts throughout Ohio, Michigan and Pennsylvania.

Thaw Bruce most recently served as managing director at Martha Stewart Living Omnimedia, of body+soul magazine. During her previous role as CEO of New Age Publishing, Jan led body+soul through its turn-around and rebranding efforts and subsequently sold the company to Martha Stewart Living Omnimedia in 2003.

The company also named Wendy Jarchow director of business development – Upper Midwest based in the Cleveland office.

Chrysalis Ventures is a leading source of equity capital for young, growing companies in Mid-America. Chrysalis invests primarily in early-and growth-stage Healthcare and Technology companies. Chrysalis has approximately $400 million under management and has invested in over 65 companies.